NCT00095160View on ClinicalTrials.gov

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Neoplasms
Interventions
DRUG

852A

Trial Locations (1)

55455

University of Minnesota, Minneapolis

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER